biote Corp (BTMD) - Total Liabilities
Based on the latest financial reports, biote Corp (BTMD) has total liabilities worth $158.01 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore biote Corp cash conversion from operations to assess how effectively this company generates cash.
biote Corp - Total Liabilities Trend (2019–2025)
This chart illustrates how biote Corp's total liabilities have evolved over time, based on quarterly financial data. Check biote Corp (BTMD) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
biote Corp Competitors by Total Liabilities
The table below lists competitors of biote Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
iBio, Inc. Common Stock
NASDAQ:IBIO
|
USA | $7.83 Million |
|
Electra Battery Materials Corp
V:ELBM
|
Canada | CA$100.05 Million |
|
Nahar Industrial Enterprises Limited
NSE:NAHARINDUS
|
India | Rs6.90 Billion |
|
Wisekey International Holding AG
NASDAQ:WKEY
|
USA | $28.43 Million |
|
Falcon Machine Tools Co Ltd
TWO:4513
|
Taiwan | NT$2.94 Billion |
|
PDS Biotechnology Corp
NASDAQ:PDSB
|
USA | $21.24 Million |
|
ImmuCell Corporation
NASDAQ:ICCC
|
USA | $15.93 Million |
|
ZEN Graphene Solutions Ltd
NASDAQ:ZTEK
|
USA | $5.18 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down biote Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BTMD company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how biote Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for biote Corp (2019–2025)
The table below shows the annual total liabilities of biote Corp from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $158.01 Million | -29.64% |
| 2024-12-31 | $224.57 Million | +17.06% |
| 2023-12-31 | $191.84 Million | +12.90% |
| 2022-12-31 | $169.92 Million | +238.45% |
| 2021-12-31 | $50.20 Million | +1.09% |
| 2020-12-31 | $49.66 Million | -12.60% |
| 2019-12-31 | $56.82 Million | -- |
About biote Corp
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with … Read more